Skip to main content
. Author manuscript; available in PMC: 2016 Mar 30.
Published in final edited form as: Curr Mol Med. 2016;16(3):222–231. doi: 10.2174/1566524016666160225151131

Fig. (2).

Fig. (2)

ALK6 expression is associated with decreased survival in early stage EOCs. (A), Kaplan-Meier overall survival curves for ALK6 positive and negative early stage EOCs. Among patients with early stage disease, presence of the ALK 6 receptor was associated with a significantly increased risk of death (p = 0.03). Patients with tumors expressing ALK6 (n = 35) were 3.2 times more likely to die than patients without ALK6 (n = 38) expression (95% CI 1.1–9.6). (B) Among patients with advanced stage disease, expression of ALK 6 receptor did not affect overall survival. Associations were evaluated based on fitting Cox proportional hazards models and summarized using the hazard ratio (HR) and corresponding 95% confidence interval (CI).